Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia C ...
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.346
https://www.valueinhealthjournal.com/article/S1098-3015(13)02251-1/fulltext
Title :
Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia C ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02251-1&doi=10.1016/j.jval.2013.08.346
First page :
A382
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
327